FDA approves drug to treat Duchenne muscular dystrophy
Feb. 9, 2017
The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.
Filed under: FDA 2017, Uncategorized Tagged: deflazacort, Duchenne muscular dystrophy, Emflaza, Emflaza deflazacort, FDA 2017 
